RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.47% | -11.57% | -11.53% | -8.26% | -28.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.47% | -11.57% | -11.53% | -8.26% | -28.13% |
| Cost of Revenue | 6.11% | -73.20% | -41.45% | -8.90% | -26.72% |
| Gross Profit | -15.46% | 173.41% | 70.89% | -6.90% | -31.79% |
| SG&A Expenses | -20.39% | 191.54% | -3.21% | 14.03% | -18.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -43.08% | -8.10% | -56.73% | -38.32% | -22.62% |
| Total Operating Expenses | -12.79% | 52.95% | -17.67% | 6.67% | -20.97% |
| Operating Income | 21.37% | -82.04% | 23.93% | -19.25% | 15.53% |
| Income Before Tax | 53.91% | -196.95% | 6.81% | -48.13% | -37.75% |
| Income Tax Expenses | -- | -16.90% | -- | -- | -- |
| Earnings from Continuing Operations | 57.61% | -196.40% | 6.81% | -48.13% | -37.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.61% | -196.40% | 6.81% | -48.13% | -37.75% |
| EBIT | 21.37% | -82.04% | 23.93% | -19.25% | 15.53% |
| EBITDA | 15.59% | -84.91% | 21.45% | -44.00% | 17.58% |
| EPS Basic | 57.75% | -195.80% | 6.15% | -50.70% | -40.59% |
| Normalized Basic EPS | 31.67% | -67.29% | 5.00% | -52.27% | 4.76% |
| EPS Diluted | 57.75% | -195.80% | 6.15% | -50.70% | -40.59% |
| Normalized Diluted EPS | 31.67% | -67.29% | 5.00% | -52.27% | 4.76% |
| Average Basic Shares Outstanding | 0.00% | 0.02% | -1.07% | -1.98% | -2.38% |
| Average Diluted Shares Outstanding | 0.00% | 0.02% | -1.07% | -1.98% | -2.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |